-
AbbVie Q3 2024 Financial statements
Financial statements
In Q3 2024, AbbVie reported net revenues of $14.460 billion, a 3.8% year-on-year increase. Skyrizi surged by 50.8% to $3.205 billion, offsetting Humira's decline due to generics. Diverse segments, including Oncology and Neuroscience, showed solid growth, while strategic acquisitions.
阆中市|
绍兴县|
横峰县|
东明县|
玛纳斯县|
阿拉善左旗|
台湾省|
侯马市|
太和县|
望奎县|
郑州市|
常宁市|
岑溪市|
徐闻县|
岳西县|
盱眙县|
开鲁县|
民丰县|
泸州市|
鱼台县|
沂源县|
沽源县|
澳门|
绥宁县|
亳州市|
阿拉善右旗|
积石山|
勐海县|
兖州市|
梨树县|
蒲城县|
临泉县|
河西区|
常德市|
新巴尔虎左旗|
新绛县|
察隅县|
开化县|
宜川县|
漠河县|
广南县|